In addition, computer-aided drug designing (CADD) has delivered numerous novel anti-cancer compounds such as Erlotinib (EGFR kinase inhibitor, suppresses Non-small cell lung carcinoma and pancreatic cancer), Sorafenib (VEGFR inhibitor, treat thyroid, renal and liver cancer), Lapatinib (for the management of ERBB2-postive breast cancer), Abiraterone (inhibits androgen production to treat metastatic castration-resistant prostate cancer or hormone-refractory prostate cancer) and Crizotinib (ALK inhibitor, to treat Non-small cell lung carcinoma) [24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39]. This evidence concerns the gene ALK and non-small cell lung carcinoma.